Reckitt has out-beaten GSK in the acquisition of Boots Healthcare International, the OTC business of the Boots Group. Boots initially expected its subsidiary to sell for around £1.2 B, but the identified cost savings and the strong potential for growth pushed the price to £1.926 B.